Dr. Justin Nickell
Dr. Justin Nickell

Justin Nickell obtained a Bachelor of Arts degree from Berea College in 2002, following which he entered the Integrated Biomedical Sciences graduate program at the University of Kentucky. During this period, Dr. Nickell gained valuable experience in in vivo electrochemistry, and aided in the development of novel technology for the field: ceramic-based, multisite microelectrodes for second-by-second detection of neurotransmitter regulation in the aging mammalian brain. Dr. Nickell is currently engaged in efforts to discover and develop a pharmacotherapeutic for individuals suffering from an addiction to methamphetamine.

Selected Publications

  • Nickell Justin Robert, Culver J P, Janganati V, Zheng Guangrong, Dwoskin Linda P, Crooks Peter A. (2016). Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2. Bioorganic & medicinal chemistry letters,
  • Nickell Justin Robert, Culver J P, Janganati V, Zheng Guangrong, Dwoskin Linda P, Crooks Peter A. (2016). 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorganic & medicinal chemistry letters, 26(13), 2997-3000.
  • Chow J J, Nickell Justin Robert, Darna M, Beckmann Joshua Shawn. (2016). Toward isolating the role of dopamine in the acquisition of incentive salience attribution. Neuropharmacology, 109, 320-331.
  • Joolakanti S R, Nickell Justin Robert, Janganati V, Zheng Guangrong, Dwoskin Linda P, Crooks Peter A. (2016). Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2. Bioorganic & medicinal chemistry letters, 26(10), 2422-7.
  • Nickell Justin Robert, Siripurapu K B, Vartak A, Crooks Peter A, Dwoskin Linda P. (2014). The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Advances in pharmacology (San Diego, Calif.), 69, 71-106.
  • Horton D B, Nickell Justin Robert, Zheng Guangrong, Crooks Peter A, Dwoskin Linda P. (2013). GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine. Journal of neurochemistry, 127(2), 177-86.
  • Nickell Justin Robert, Grinevich V P, Siripurapu K B, Smith Andrew, Dwoskin Linda P. (2013). Potential therapeutic uses of mecamylamine and its stereoisomers. Pharmacology, biochemistry, and behavior, 108, 28-43.
  • Meyer A C, Horton D B, Neugebauer N M, Wooters T E, Nickell Justin Robert, Dwoskin Linda P, Bardo Michael. (2011). Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration. Neuropharmacology, 61(4), 849-56.
  • Nickell Justin Robert, Zheng Guangrong, Deaciuc A G, Crooks Peter A, Dwoskin Linda P. (2011). Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2. The Journal of pharmacology and experimental therapeutics, 336(3), 724-33.
  • Nickell Justin Robert, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu K B, Zheng Guangrong, Crooks Peter A, Dwoskin Linda P. (2010). Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. The Journal of pharmacology and experimental therapeutics, 332(2), 612-21.